Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy

Introduction Phosphoenolpyruvate carboxykinase 1 (PCK1) is an essential enzyme of the gluconeogenic pathway, which can affect kidney physiology in various ways. Nevertheless, its role in the progression of IgA nephropathy (IgAN) remains to be elucidated.Methods We identified the differentially expre...

Full description

Saved in:
Bibliographic Details
Main Authors: Ya-yin Tan, Yu-kai Wang, Xiao-mei Luo, Chao-yi Chen, Xue-qi Liu, Xin-ran Liu, Yong-gui Wu
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Renal Failure
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2508297
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850185133976453120
author Ya-yin Tan
Yu-kai Wang
Xiao-mei Luo
Chao-yi Chen
Xue-qi Liu
Xin-ran Liu
Yong-gui Wu
author_facet Ya-yin Tan
Yu-kai Wang
Xiao-mei Luo
Chao-yi Chen
Xue-qi Liu
Xin-ran Liu
Yong-gui Wu
author_sort Ya-yin Tan
collection DOAJ
description Introduction Phosphoenolpyruvate carboxykinase 1 (PCK1) is an essential enzyme of the gluconeogenic pathway, which can affect kidney physiology in various ways. Nevertheless, its role in the progression of IgA nephropathy (IgAN) remains to be elucidated.Methods We identified the differentially expressed genes in the glomeruli of IgAN patients through weighted gene co-expression network analysis across three datasets. Through clinical renal pathological tissue and cellular experiments, we further validated the gene and investigated its relationship with the inflammatory markers and fibrosis indicators in IgAN.Results Compared to peritumoral normal tissues, the peroxisome proliferator-activated receptor γ (PPARγ) signaling pathway have been identified as key elements in IgAN pathogenesis from two GEO databases and a validation dataset. PCK1 was identified and validated as one of the most promising candidate genes. The expression of PCK1 in clinically collected kidney specimens was significantly downregulated in patients with IgAN compared to healthy controls. The expression of PCK1 was inversely correlated with clinical indicators such as urinary albumin-to-creatinine ratio, 24-hour proteinuria. In experiments with SV40-transformed mouse glomerular mesangial cells (MCs), PCK1 and PPARγ protein expression levels were significantly decreased in polymeric IgA1 (pIgA1)-stimulated MCs, which contrasts with the increased expression of inflammatory and fibrotic factors. Overexpression of PCK1 inhibited cellular inflammation and fibrotic changes induced by pIgA1, demonstrating protective effects against cellular fibrosis similar to rosiglitazone.Conclusion PCK1 exerted a pronounced inhibitory effect on mesangial cell inflammatory markers and fibrosis indicators in IgAN, potentially offering a novel therapeutic target for its treatment.
format Article
id doaj-art-eb70ce1c259846e68aef69dd65a0a068
institution OA Journals
issn 0886-022X
1525-6049
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Renal Failure
spelling doaj-art-eb70ce1c259846e68aef69dd65a0a0682025-08-20T02:16:49ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492025-12-0147110.1080/0886022X.2025.2508297Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathyYa-yin Tan0Yu-kai Wang1Xiao-mei Luo2Chao-yi Chen3Xue-qi Liu4Xin-ran Liu5Yong-gui Wu6Department of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR ChinaIntroduction Phosphoenolpyruvate carboxykinase 1 (PCK1) is an essential enzyme of the gluconeogenic pathway, which can affect kidney physiology in various ways. Nevertheless, its role in the progression of IgA nephropathy (IgAN) remains to be elucidated.Methods We identified the differentially expressed genes in the glomeruli of IgAN patients through weighted gene co-expression network analysis across three datasets. Through clinical renal pathological tissue and cellular experiments, we further validated the gene and investigated its relationship with the inflammatory markers and fibrosis indicators in IgAN.Results Compared to peritumoral normal tissues, the peroxisome proliferator-activated receptor γ (PPARγ) signaling pathway have been identified as key elements in IgAN pathogenesis from two GEO databases and a validation dataset. PCK1 was identified and validated as one of the most promising candidate genes. The expression of PCK1 in clinically collected kidney specimens was significantly downregulated in patients with IgAN compared to healthy controls. The expression of PCK1 was inversely correlated with clinical indicators such as urinary albumin-to-creatinine ratio, 24-hour proteinuria. In experiments with SV40-transformed mouse glomerular mesangial cells (MCs), PCK1 and PPARγ protein expression levels were significantly decreased in polymeric IgA1 (pIgA1)-stimulated MCs, which contrasts with the increased expression of inflammatory and fibrotic factors. Overexpression of PCK1 inhibited cellular inflammation and fibrotic changes induced by pIgA1, demonstrating protective effects against cellular fibrosis similar to rosiglitazone.Conclusion PCK1 exerted a pronounced inhibitory effect on mesangial cell inflammatory markers and fibrosis indicators in IgAN, potentially offering a novel therapeutic target for its treatment.https://www.tandfonline.com/doi/10.1080/0886022X.2025.2508297IgA nephropathyPCK1PPARγinflammationfibrosis
spellingShingle Ya-yin Tan
Yu-kai Wang
Xiao-mei Luo
Chao-yi Chen
Xue-qi Liu
Xin-ran Liu
Yong-gui Wu
Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy
Renal Failure
IgA nephropathy
PCK1
PPARγ
inflammation
fibrosis
title Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy
title_full Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy
title_fullStr Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy
title_full_unstemmed Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy
title_short Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy
title_sort protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of iga nephropathy
topic IgA nephropathy
PCK1
PPARγ
inflammation
fibrosis
url https://www.tandfonline.com/doi/10.1080/0886022X.2025.2508297
work_keys_str_mv AT yayintan protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy
AT yukaiwang protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy
AT xiaomeiluo protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy
AT chaoyichen protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy
AT xueqiliu protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy
AT xinranliu protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy
AT yongguiwu protectiveeffectofphosphoenolpyruvatecarboxykinase1oninflammationandfibroticprogressionofiganephropathy